GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-2,709 Cr | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹-2,709 Cr |
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-2,709 Cr | Negative | |
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹71,041.0 Cr | 5.5% | 14.9% | 26.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹460,696.0 Cr | 0.5% | -4% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,063.0 Cr | 9.1% | 18.2% | 47.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,515.0 Cr | 3.6% | 3.4% | 36.4% | Stock Analytics | |
| CIPLA | ₹114,554.0 Cr | -1.2% | -3.3% | -10.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,308.6 Cr | -1.4% | 2.9% | -8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 5.5% |
14.9% |
26.8% |
| SENSEX | -0.4% |
-0.5% |
-5.8% |
You may also like the below Video Courses